Low incidence of recurrent Buruli ulcers in treated Australian patients living in an endemic region

PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006724. doi: 10.1371/journal.pntd.0006724. eCollection 2018 Aug.

Abstract

We examined recurrent Buruli ulcer cases following treatment and assumed cure in a large cohort of Australian patients living in an endemic area. We report that while the recurrence rate was low (2.81 cases/year/1000 population), it remained similar to the estimated risk of primary infection within the general population of the endemic area (0.85-4.04 cases/year/1,000 population). The majority of recurrent lesions occurred in different regions of the body and were separated by a median time interval of 44 months. Clinical, treatment and epidemiological factors combined with whole genome sequencing of primary and recurrent isolates suggests that in most recurrent cases a re-infection was more likely as opposed to a relapse of the initial infection. Additionally, all cases occurring more than 12 months after commencement of treatment were likely re-infections. Our study provides important prognostic information for patients and their health care providers concerning the nature and risks associated with recurrent cases of Buruli ulcer in Australia.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Australia
  • Buruli Ulcer / drug therapy
  • Buruli Ulcer / epidemiology*
  • Buruli Ulcer / microbiology
  • Buruli Ulcer / pathology
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium ulcerans / genetics*
  • Phylogeny
  • Recurrence
  • Risk Factors
  • Time Factors
  • Young Adult

Substances

  • Anti-Bacterial Agents

Grants and funding

The authors received no specific funding for this work.